Physician profile
Aron Ethiopia Kefela
NPI 1932374980
$591,488.24
in general payments reported to CMS, 2019-2025
75 companies · $75K in 2025
The $75K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $27K · 2021: $108K · 2022: $137K · 2023: $114K · 2024: $83K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $158K · Consulting Fee: $49K · Travel and Lodging: $35K · Food and Beverage: $19K · Honoraria: $11K · Education: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $158,136.00 |
| Consulting Fee | $48,725.50 |
| Travel and Lodging | $34,749.96 |
| Food and Beverage | $19,428.54 |
| Honoraria | $10,531.00 |
| Education | $674.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $133,737.66 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Janssen Biotech, INC. | $104,579.25 | 2019-2025 | Carvykti, Darzalex, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $99,993.33 | 2019-2025 | Opdivo, Opdualag |
| Coherus Oncology, INC. | $65,991.10 | 2020-2025 | Loqtorzi |
| Amgen INC. | $65,470.51 | 2019-2023 | Kyprolis, Nplate, Vectibix |
| Janssen Pharmaceuticals, INC | $50,889.97 | 2019-2023 | Xarelto |
| Pfizer INC. | $22,302.12 | 2019-2025 | |
| Array Biopharma INC | $12,946.45 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Astrazeneca Pharmaceuticals Lp | $6,314.55 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Ipsen Biopharmaceuticals, INC | $4,053.76 | 2019-2022 | |
| Genentech USA, INC. | $3,761.23 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Genzyme Corporation | $3,700.05 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,864.19 | 2021 | |
| R-Pharm US LLC | $1,322.65 | 2019 | |
| Secura Bio, INC. | $1,062.85 | 2021-2025 | Copiktra |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,010.59 | 2019-2025 | Piqray, Kisqali |
| Celgene Corporation | $970.44 | 2019-2023 | Pomalyst |
| Astellas Pharma US INC | $881.79 | 2020-2025 | Xtandi, Vyloy |
| Abbvie INC. | $832.71 | 2023-2025 | |
| Seagen INC. | $824.86 | 2019-2024 | Adcetris, Tukysa, Tivdak |
| Merck Sharp & Dohme LLC | $624.49 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $565.57 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Eisai INC. | $513.40 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $446.29 | 2019-2025 | Libtayo |
| Adc Therapeutics America, INC. | $409.42 | 2021-2024 | |
| Stemline Therapeutics INC. | $397.61 | 2023-2025 | Orserdu |
| Glaxosmithkline, LLC. | $368.28 | 2021-2025 | Ojjaara, Blenrep, Shingrix |
| Legend Biotech USA INC. | $367.63 | 2024-2025 | Carvykti |
| Exelixis INC. | $361.18 | 2019-2025 | Cabometyx |
| Celltrion USA INC. | $328.67 | 2023-2024 | Vegzelma |
| Sobi, INC | $301.54 | 2022-2025 | |
| Incyte Corporation | $290.25 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Jazz Pharmaceuticals INC. | $279.17 | 2022-2025 | Zepzelca |
| Bayer Healthcare Pharmaceuticals INC. | $261.02 | 2019-2025 | |
| Gilead Sciences, INC. | $233.21 | 2019-2025 | Trodelvy |
| Beone Medicines USA, INC. | $212.49 | 2025 | Brukinsa, Tevimbra |
| Karyopharm Therapeutics INC. | $211.85 | 2020-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $211.23 | 2020-2025 | Alunbrig, Iclusig, Ninlaro |
| Genmab U.S., INC. | $204.85 | 2025 | Epkinly |
| Sanofi-Aventis U.S. LLC | $177.98 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $164.15 | 2024-2025 | Clonoseq |
| Pharmacyclics LLC, An Abbvie Company | $155.59 | 2019-2023 | Imbruvica |
| Deciphera Pharmaceuticals INC. | $139.12 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Epizyme, INC. | $134.19 | 2022-2023 | Tazverik |
| Puma Biotechnology, INC. | $124.74 | 2019-2025 | |
| Lilly USA, LLC | $112.24 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Blueprint Medicines Corporation | $111.13 | 2022-2025 | Ayvakit |
| Varian Medical Systems, INC. | $105.29 | 2020 | |
| Alexion Pharmaceuticals, INC. | $100.31 | 2019-2025 | Ultomiris |
| Pharmaessentia USA Corporation | $91.80 | 2024-2025 | Besremi |
| Emd Serono, INC. | $89.26 | 2024-2025 | |
| Tersera Therapeutics LLC | $82.26 | 2019-2025 | Xermelo, Zoladex |
| Beigene USA, INC. | $65.31 | 2023-2025 | Brukinsa, Tevimbra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.71 | 2023 | Gilotrif |
| Springworks Therapeutics, INC. | $61.57 | 2024-2025 | Ogsiveo, Gomekli |
| Foundation Medicine, INC. | $56.84 | 2022-2023 | |
| Caris Mpi, INC. | $52.97 | 2025 | Mi Cancer Seek |
| Tesaro, INC. | $48.52 | 2019 | |
| Agios Pharmaceuticals, INC. | $44.07 | 2024-2025 | Pyrukynd |
| Kite Pharma, INC. | $43.92 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $43.73 | 2024 | Cosela |
| Clovis Oncology, INC. | $35.45 | 2019-2020 | |
| Taiho Oncology, INC. | $34.71 | 2025 | |
| Servier Pharmaceuticals LLC | $29.93 | 2025 | |
| Mirati Therapeutics, INC. | $28.82 | 2023-2024 | Krazati |
| Nuvation Bio INC. | $25.67 | 2025 | Ibtrozi |
| Avyxa Pharma, LLC | $24.19 | 2025 | |
| Sumitomo Pharma America, INC. | $23.28 | 2025 | Orgovyx |
| Tempus Ai, INC | $20.89 | 2025 | Xt Cdx |
| Partner Therapeutics, INC. | $19.14 | 2019 | |
| Aveo Pharmaceuticals, INC. | $18.84 | 2024 | |
| G1 Therapeutics, INC. | $17.63 | 2023 | Cosela |
| Mylan Institutional INC. | $16.47 | 2022 | |
| Biomarin Pharmaceutical INC. | $13.97 | 2023 | Roctavian |
| Kyowa Kirin, INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aron Kefela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.